Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.42 |
| ▸ | FLT4 | P35916 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.38 |
| ▸ | CEPT1 | Q9Y6K0 | 3/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544453 | 0.89 | ALOX5 (0.44) | ALOX5FLT1FLT4KDRROCK2 | |
| SCHEMBL2338367 | 0.79 | ALOX5 (0.47) | ALOX5FLT1FLT4KDRIMPDH2 | |
| SCHEMBL3303142 | 0.79 | FLT1 (0.42) | ALOX5FLT1FLT4KDRIMPDH2 | |
| SCHEMBL2339289 | 0.76 | FLT1 (0.50) | ALOX5FLT1FLT4KDRIMPDH2 | |
| SCHEMBL544048 | 0.75 | MAPK14 (0.46) | FLT1FLT4KDRIMPDH2ROCK2 | |
| SCHEMBL2343055 | 0.74 | ALOX5 (0.45) | ALOX5FLT1FLT4KDRIMPDH2 | |
| SCHEMBL5712006 | 0.74 | ROCK2 (0.48) | FLT1FLT4KDRIMPDH2ROCK2 | |
| SCHEMBL27710427 | 0.74 | ALOX5 (0.43) | ALOX5FLT1FLT4KDRIMPDH2 | |
| SCHEMBL3303136 | 0.74 | CSF1R (0.55) | KDR | |
| SCHEMBL543650 | 0.74 | ALDH1A1 (0.42) | ALOX5FLT1FLT4KDRIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | claimed |
| EP-1684750-B1 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2010-04-28 | — | — | EP | claimed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | claimed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | claimed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | claimed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2010-05-06 | — | — | US | disclosed |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2010-05-06 | — | — | US | disclosed |
| EP-1684750-B1 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | AB SCIENCE | 2008-06-19 | — | — | US | disclosed |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | AB SCIENCE (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | MOUSSY ALAIN | 2007-10-25 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | KIT, CPA3, CMA1 | ALOX5 3590/4885FLT1 1427/4885FLT4 768/4885 |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | ALOX5 1979/4885FLT1 791/4885FLT4 379/4885 |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, ABL1, FLT3 | ALOX5 3180/4885FLT1 17/4885FLT4 13/4885 |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | KIT, JAK3, MAP3K3 | ALOX5 3283/4885FLT1 188/4885FLT4 91/4885 |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | KIT, CPA3, CMA1 | ALOX5 1082/4885FLT1 1829/4885FLT4 1230/4885 |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, FLT3, ABL1 | ALOX5 3526/4885FLT1 25/4885FLT4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.